Avacta Group Plc (AIM:AVCT)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 358.09M +178.3% |
| Revenue (ttm) | 113.00K |
| Net Income | -38.61M |
| EPS | -0.10 |
| Shares Out | 453.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,144,286 |
| Open | 78.50 |
| Previous Close | 79.00 |
| Day's Range | 77.00 - 82.00 |
| 52-Week Range | 26.00 - 92.00 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 86.50 (+11.47%) |
| Earnings Date | May 19, 2026 |
About Avacta Group
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv... [Read more]
Financial Performance
In 2025, Avacta Group's revenue was 113,000, a change of 0.00% compared to the previous year's 113,000. Losses were -38.61 million, -26.93% less than in 2024.
Financial StatementsNews
Avacta Group Earnings Call Transcript: H2 2025
Focused on oncology, the company advanced its pre|CISION platform with strong R&D investment, achieved key clinical milestones, and extended its cash runway into early 2027. Multiple clinical data readouts and partnering opportunities are expected in the next 12 months.
Avacta Group Annual report: H2 2025
Avacta Group has published its H2 2025 annual report on May 19, 2026.
Avacta Group Slides: Corporate presentation
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Avacta Group Earnings release: H2 2025
Avacta Group released its H2 2025 earnings on January 20, 2026, summarizing the period's financial results.
Avacta Group Transcript: Study Update
Phase 1B data for AVA6000 in salivary gland cancer show a 90% disease control rate, strong safety profile, and effective tumor targeting even in low-FAP patients. Ongoing enrollment and survival data will inform a randomized Phase 2/3 trial.
Avacta Group Press release: Study Update
Avacta Group issued a press release on December 17, 2025, disclosing material business information to investors.
Avacta Group Slides: Study Update
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on December 17, 2025.
Avacta Group Transcript: Status Update
The dual-payload pre|CISION platform enables targeted, simultaneous delivery of two drugs to tumors, overcoming resistance and reducing toxicity. Clinical progress continues with AVA6103 on track for a 2026 trial, a strengthened IP portfolio, and a cash runway into late 2026 supporting multiple upcoming catalysts.
Avacta Group Earnings Call Transcript: H1 2025
Interim results highlight strong progress in clinical and preclinical oncology programs, with AVA6000 and AVA6103 advancing on schedule. Financial position is stable with a cash runway into Q1 2026, and strategic partnerships are prioritized to support future development.
Avacta Group Quarterly report: H1 2025
Avacta Group has published its H1 2025 quarterly earnings report on September 30, 2025.
Avacta Group Slides: H1 2025
Avacta Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 30, 2025.
Avacta Group Slides: Corporate Presentation
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2025.
Avacta Group Earnings release: Trading Update
Avacta Group released its earnings on July 2, 2025, summarizing the period's financial results.
Avacta Group Earnings release: Trading Update
Avacta Group released its earnings on July 2, 2025, summarizing the period's financial results.
Avacta Group Transcript: AGM 2025
The AGM highlighted significant progress in clinical programs, strengthened leadership, and ongoing strategic partnerships. Financial challenges from the Heights Convertible Bond remain a key focus, with cash management and upcoming data catalysts expected to drive future growth.
Avacta Group Earnings Call Transcript: H2 2024
Transitioned to a pure-play oncology biotech, advancing FAPDOX and FAP-Exatecan with strong clinical and preclinical progress. Financial runway extends into Q1 2026, with additional funding and partnerships actively pursued. Key data catalysts expected in late 2025 and 2026.
Avacta Group Annual report: H2 2024
Avacta Group has published its H2 2024 annual report on June 6, 2025.
Avacta Group Annual report: H2 2024
Avacta Group has published its H2 2024 annual report on June 6, 2025.
Avacta Group Slides: H2 2024
Avacta Group has posted slides in relation to its H2 2024 quarterly earnings report, which was published on June 6, 2025.
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life scien...